Rumalon injection solution 1ml, No. 25

Degenerative-dystrophic diseases of the joints:

• gonarthrosis;

• arthrosis of the interphalangeal joints;

• coxarthrosis;

• spondylosis;

• spondyloarthrosis;

• meniscopathy;

• chondromalacia of the patella.

The drug is injected deeply into the / m: on the 1st day - 0.3 ml, on the 2nd day - 0.5 ml and then 3 times a week, 1 ml for 5-6 weeks. A second course of treatment - after consulting a doctor according to the same scheme.

Solution for intramuscular administration from pale yellow with a brownish tinge to yellowish brown, transparent, with the smell of metacresol.

1 amp.

glycosaminoglycan-peptide complex 1 ml

• Hypersensitivity to the components of the drug;

• rheumatoid arthritis;

• age under 18;

• pregnancy;

• breastfeeding period;

• use in women of reproductive age who do not follow reliable methods of contraception.

pharmachologic effect

Tissue repair stimulant. Combined preparation of animal origin, contains a glycosaminoglycan-peptide complex. The effect of the drug is due to the combined effect of its active components. Normalizes metabolism in cartilaginous hyaline tissue: enhances the biosynthesis of sulfated mucopolysaccharides and collagen, stimulates the regeneration of articular cartilage, reduces enzyme activity and inhibits catabolic processes in cartilage tissue.

Pharmacokinetics

No studies have been conducted.

Side effect

From the immune system: rarely - allergic reactions, incl. anaphylactoid reactions, anaphylactic shock. If these or any other side effects appear, the patient should stop using the drug and inform the attending physician about it.

Application during pregnancy and lactation

The use of the drug during pregnancy and during breastfeeding is contraindicated (due to the lack of information on the use of the drug in these groups of patients).

special instructions

With simultaneous use with indirect anticoagulants, antiplatelet agents and fibrinolytics, frequent monitoring of blood coagulation parameters is necessary.

Influence on the ability to drive vehicles and mechanisms

The use of the drug does not affect the ability to perform potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions (driving, working with moving mechanisms, the work of a dispatcher and an operator).

Overdose

To date, no cases of overdose have been reported.

Drug interactions

The drug RumalonЃ can be used simultaneously with NSAIDs and GCS. With simultaneous use with indirect anticoagulants, antiplatelet agents and fibrinolytics, their effect may be enhanced.